Comparison of hormonal and metabolic phenotype in carriers of genetic markers of sensitivity to metformin who have or do not have cancer
Vol. 60 No. 6 (2014), Articles
Vol. 60 No. 6 (2014)

Comparison of hormonal and metabolic phenotype in carriers of genetic markers of sensitivity to metformin who have or do not have cancer

Articles
https://doi.org/10.37469/0507-3758-2014-60-6-707-712
Published 15.12.2014
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
##article.numberofdownloads## 32
##article.numberofviews## 51
PDF (Русский)

Keywords

cancer
diabetes
metformin
sensitivity
markers

How to Cite

, , & . (2014). Comparison of hormonal and metabolic phenotype in carriers of genetic markers of sensitivity to metformin who have or do not have cancer. Voprosy Onkologii, 60(6), 707–712. https://doi.org/10.37469/0507-3758-2014-60-6-707-712
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

In comparative evaluation of hormonal and metabolic status in carriers of genetic markers of potential response to antidiabetic biguanide metformin in groups of patients with diabetes (postmenopausal women with newly diagnosed cancer or without it) as well as in cancer patients without diabetes and healthy women it was found that: a) polymorphisms of a gene transporter 1 of organic cations (OCT1) and a gene of sex hormone-binding globulin SHBG, D356N rs6259 (GA) could not only predict the potential sensitivity to metformin, but their carriers were characterized by certain differences of hormonal and metabolic phenotype; b) similar hormonal and metabolic features were mainly associated with nonsteroidal component and were identified mostly in patients with diabetes with or without newly discovered cancer; c) at the same time the presence of cancer was not an obstacle for orientation to both the hormonal and metabolic and genetic parameters in deciding on the possibility of metformin administration, which, however, needs verification by using the same indicators in conditions of the real use of the drug.
https://doi.org/10.37469/0507-3758-2014-60-6-707-712
##article.numberofdownloads## 32
##article.numberofviews## 51
PDF (Русский)

References

Берштейн Л.М. Рак гормонозависимых тканей в системе основных неинфекционных заболеваний человека. СПб.: Эскулап. 2009, - 180 с.

Берштейн Л.М., Васильев Д.А., Порошина Т.Е. и др. Гормонально-метаболические особенности постменопаузальных женщин с впервые выявленным сахарным диабетом: роль онкологического заболевания и наследственной предрасположенности к диабету // Вестник РАМН. - 2013. - N2. - С. 29-34.

Берштейн Л.М., А.Г. Иевлева, Васильев Д.А. Потенциальная чувствительность к метформину больных диабетом, имеющих сопутствующую онкопатологию и без таковой: фармакогенетический анализ // Вестн. РАМН. - 2013. - N12. - С. 58-63

Anisimov V.N. Do metformin a real anticarcinogen? A. critical reappraisal of experimental data // Ann. Transl. Med. - 2014. http://dx.doi.org/10.3978/j.issn.2305-5839.2014.06.02

Avery C.L., He Q., North K.E. et al. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains // PLoS Genet. - 2011. - Vol. 7 (10). - e1002322.

Berstein L.M. Metformin in obesity, cancer and aging: addressing controversies // Aging (Albany NY). - 2012. - Vol. 4 (5). - P. 320-329.

Berstein L.M., lyevleva A.G., Vasilyev D.A. et al. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer // Cell Cycle. - 2013. - Vol. 12 (23). - P. 3681-3688.

Christensen M.M., Brasch-Andersen C., Green H. et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c // Pharmacogenet Genomics. - 2011. - Vol. 21 (12). - P. 837-850.

Corbellini A., Lugaro G., Giannattasio G., Torti G. Research on the antitumoral activity of the biguanides. IV // Arch Ital Patol Clin Tumori. - 1967. - Vol. 10 (3). - P. 197-210.

Dilman V.M., Berstein L.M., Ostroumova M.N. et al. Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances // Oncology. - 1982. - Vol. 39 (1). - P. 13-19.

Ong C.R., Molyneaux L.M., Constantino M.l. et al. Longterm efficacy of metformin therapy in nonobese individuals with type 2 diabetes // Diabetes Care. - 2006. - Vol. 29. - P. 2361-2364.

Pawlyk A.C., Giacomini K.M., McKeon C. et al. Metformin pharmacogenomics: current status and future directions // Diabetes. - 2014. - Vol. 63 (8). - P. 2590-2599.

Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. - 1985. - Vol. 28 (7). - P. 412-419.

Ong C.R., Molyneaux L.M., Constantino M.l. et al. Longterm efficacy of metformin therapy in nonobese individuals with type 2 diabetes // Diabetes Care. - 2006. - Vol. 29. - P. 2361-2364.

Pawlyk A.C., Giacomini K.M., McKeon C. et al. Metformin pharmacogenomics: current status and future directions // Diabetes. - 2014. - Vol. 63 (8). - P. 2590-2599.

Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning // Cancer Discov. - 2012. - Vol. 2 (9). - P. 778-790.

Robert F., Fendri S., Hary L. et al. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects» // Diabetes Metab. - 2003. - Vol. 29 (3). - P. 279-283.

Suissa S., Azoulay L. Metformin and cancer: mounting evidence against an association // Diabetes Care - 2014. - Vol. 37 (7). - P. 1786-1788.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...